[Translation] A single-center, open-label, randomized, single-dose, four-period, fully replicated, two-sequence, crossover bioequivalence study of paroxetine hydrochloride enteric-coated extended-release tablets in healthy adult participants in a postprandial state.
主要目的:
本试验以上海海虹实业(集团)巢湖今辰药业有限公司生产的盐酸帕罗西汀肠溶缓释片为受试制剂,以盐酸帕罗西汀肠溶缓释片(赛乐特®CR),BORA PHARMACEUTICAL SERVICES INC.生产,持证商:GLAXOSMITHKLINE INC.为参比制剂,评估受试制剂和参比制剂在餐后状态下的生物等效性。
次要目的:观察受试制剂和参比制剂在试验参与者中的安全性。
[Translation] Primary Objective: This study used paroxetine hydrochloride enteric-coated extended-release tablets manufactured by Shanghai Haihong Industrial (Group) Chaohu Jinchen Pharmaceutical Co., Ltd. as the test formulation and paroxetine hydrochloride enteric-coated extended-release tablets (Seroxetine® CR), manufactured by BORA PHARMACEUTICAL SERVICES INC., licensee: GLAXOSMITHKLINE INC., as the reference formulation to evaluate the bioequivalence of the test and reference formulations in the postprandial state.
Secondary Objective: To observe the safety of the test and reference formulations in study participants.